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Abstract: Objectives: High cystatin C(CysC) levels are associated with impaired cardiovascular
outcome. Whether CysC levels are independently related to the atherosclerosis burden is still
controversial. Methods: We enrolled 31 non-ST-segment elevation acute coronary syndrome
patients undergoing percutaneous coronary intervention. Patients were divided into 2 groups
on the basis of median value of serum CysC. Using the high CysC group as a dependent variable,
univariable and multivariable analyses were used to evaluate the association between CysC and
three different features of atherosclerosis: 1) coronary plaque vulnerability as assessed by optical
coherence tomography (OCT), 2) coronary artery calcium (CAC) by means of computed tomography
scan, and 3) aortic wall metabolic activity, as assessed using 18F-Fluorodeoxyglucose-positron
emission tomography (18F-FDG-PET). Results: After univariable and multivariable analyses,
18F-FDG uptake in the descending aorta (DA) was independently associated with a low level of
CysC [(Odds Ratio = 0.02; 95%CI 0.0004–0.89; p = 0.044; 18F-FDG uptake measured as averaged
maximum target to blood ratio); (Odds Ratio = 0.89; 95%CI 0.82–0.98, p = 0.025; 18F-FDG uptake
measured as number of active slices)]. No trend was found for the association between CysC and
characteristics of OCT-assessed coronary plaque vulnerability or CAC score. Conclusions: In patients
with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), 18F-FDG uptake in the DA
was associated with a low level of serum CysC. There was no relation between CysC levels and
OCT-assessed coronary plaque vulnerability or CAC score. These findings suggest that high levels of
CysC may not be considered as independent markers of atherosclerosis.
Keywords: cystatin C; 18F-fluorodeoxyglucose-positron emission tomography; frequency
domain-optical coherence tomography; coronary artery calcium score; non-ST-segment elevation
acute coronary syndrome
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1. Introduction
Cystatin C, a 13-kDa protein, is a member of a family of competitive inhibitors of lysosomal
cysteine proteases synthesized in all nucleated cells at a constant rate [1]. Because of its small free
filtration in the glomerulus, its complete reabsorption in the proximal tubule, and lack of tubular
secretion, it has been proposed as a more reliable marker of renal function than serum creatinine [2,3].
Cystatin C has also emerged as a marker of cardiovascular risk since high levels of circulating cystatin C
have been shown to be consistently and strongly associated with cardiovascular outcomes, in different
clinical scenarios [4,5]. However, the mechanisms linking increased cystatin C levels and impaired
cardiovascular outcome are not completely understood, so far, although renal dysfunction is a definite
plausible link. Early studies suggested that raised cystatin C levels identify a ‘preclinical’ kidney
dysfunction that may be associated with adverse clinical outcomes [6]. Most recently, Shlipak et al. [7],
in a large meta-analysis of 11 general-population studies and 5 studies with subjects suffering from
chronic renal disease, showed that use of cystatin C for estimation of the glomerular filtration rate
(eGRF) improved the role of renal function in risk classification with reference to all-cause mortality,
cardiovascular mortality, and renal failure. On the other hand, since elastolytic cysteine proteases and
their inhibitors are involved in the pathogenesis of atherosclerosis, it has also been suggested that
cystatin C levels may be directly linked to the development and progression of atherosclerosis [8,9].
However, mendelian randomization studies [10,11] have shown that the association between cystatin
C and cardiovascular disease is not causal. Nonetheless, its role as a marker of atherosclerosis (reverse
causality) is still controversial. Therefore, we designed the present study enrolling patients with first
non-ST-segment elevation acute coronary syndrome (NSTE-ACS) to evaluate the relationship between
serum cystatin C levels and different features of atherosclerosis, namely, 1) characteristics of coronary
plaque vulnerability as assessed by optical coherence tomography (OCT), 2) coronary artery calcium
(CAC) by means of computed tomography (CT) scan, and 3) aortic wall inflammation as assessed by
18F-Fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET).
2. Materials and Methods
The present study is a pre-specified subanalysis of a study aimed at evaluating the relationship
between aortic inflammation as assessed using 18F-FDG-PET and features of coronary plaque
vulnerability as assessed using OCT [12]. Briefly, we prospectively enrolled consecutive patients with
NSTE-ACS referred to the S. Orsola/Malpighi Hospital Catheterization Laboratory and scheduled
for percutaneous coronary intervention (PCI) for at least 1 coronary obstruction in one of the main
three epicardial vessels. Inclusion and exclusion criteria have been previously described in detail [12].
Of note, although diabetes mellitus is one of the major cardiovascular risk factors, it was included in
the exclusion criteria since it is known that high levels of prescan glucose value reduce aortic 18F-FDG
uptake and increase blood pool activity [13]. In addition to the evaluation of routine hematological
and biochemical profiles, for the purpose of this sub-study an additional tube was drawn for the
determination of serum Cystatin C. Serum levels of C-reactive protein (CRP) were measured using
the immunoturbidimetric method [14] (AU 5800, Beckman Coulter, Brea, California, United States).
Intra- and inter-individual coefficients of variation were 3.22% and 3.79%, respectively. Serum levels of
cystatin C were measured using the nephelometric method [15] (Image 800, Beckman Coulter, Brea,
California, United States). Intra- and inter-individual coefficients of variation ranged from 1.6% to
1.8% and 2.3% to 2.9%, respectively.
Coronary angiography and angioplasty was performed either via the trans-radial or the
trans-femoral approach with the use of a 6F sheath [16]. Standard techniques and medications were
used. Three vessel OCT acquisition and analyses were previously described [12,17,18]. For each patient
the number of lipid-rich plaques and lipid-rich plaques with macrophages and thin cap fibroatheromas
(TCFAs) were established.
All patients underwent 18F-FDG-PET/Computed tomography (CT) >24 h after successful PCI
procedure and before discharge. Patients preparation and 18F-FDG-PET/CT protocol were previously
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described [12]. 18F-FDG uptake was measured within the wall of both the ascending aorta (AA) and
thoracic descending aorta (DA). Superior vena cava was used to calculate the blood pool background
SUV with a 1 cm standard region of interest. SUV values (maximum and mean) were calculated
on an axial plane slice by slice (every 3.75 mm) around the wall of both the AA and DA. For each
aortic slice, the mean and maximum target to background ratio (TBRmean and TBRmax, respectively)
was calculated by dividing the SUVmean and SUVmax of the aorta with the SUVmean of the superior
vena cava. Subsequently, TBRmean and TBRmax were averaged for both the AA and DA [19]. We also
calculated the number of active slices in both the AA and DA. 18F-FDG-PET slices were defined as
active if TBRmax was ≥1.6, as previously described [19].
Coronary calcification was evaluated using standardized methods as previously described [20].
Low attenuation CT scanning was performed using a tube voltage of 120 kV and 80 mA and slice
thickness of 3.75 mm. Previous studies have demonstrated that CAC scores measured on CT scan
images obtained from a hybrid PET-CT scanner are comparable with those obtained on a dedicated CT
scanner [21]. CAC score was measured in a blind fashion by a separate investigator (F.B.) from those
who performed the PET analyses.
Categorical data are expressed as proportions and continuous variables reported as medians
(25th–75th percentiles). Patients were divided into low cystatin C group and high cystatin C
group, on the basis of the median value of serum cystatin C. For comparisons between groups,
the Fisher chi-square test and Whitney’s test were used for categorical and continuous variables,
respectively. Correlations between cystatin C and features of atherosclerosis modelled as continuous
variables were determined using the Spearman’s rank correlation test. The independent association
between serum cystatin C and the different features of atherosclerosis (namely characteristics of
coronary plaque vulnerability, CAC, and aortic metabolic activity) were evaluated using the high
cystatin C group as dependent variable by means of univariable and multivariable logistic regression.
The multivariable model included both the modified diet in renal disease-estimated glomerular
filtration rate (MDRD-eGFR) and CRP as confounders. A p value <0.05 in the two-tailed tests was
considered significant. All analyses were performed with STATA 14.0 software (STATA Corporation,
College Station, Tex).
3. Results
Figure 1 shows the study flow chart. Among 77 patients screened, 47 were initially enrolled.
Of these, 13 were excluded after angiography, 1 withdrew consent for study participation, and 2 had
missing cystatin C values. Therefore, the study population comprised 31 NSTE-ACS patients treated
with PCI. Three patients refused to undergo FDG-PET but still agreed to participate to the study.
Baseline characteristics are shown in Table 1. The median age of the study population was 65 (55–72)
years, and 26 patients (84%) were male. They had a high prevalence of classical risk factor. Ischemic
changes of ECG (ST deviation or inverted T waves) were observed in 21 cases (68%). The median values
of creatinine and MDRD e-GFR were 0.94 mg/dL (0.77–1.02) and 87 mL/min/1.73 m2, respectively.
The median value of cystatin C was 0.95 mg/mL (0.88–1.08). There were no differences in baseline
characteristics between the two study groups, with the exception of CRP values. Indeed, patients with
low level of cystatin C showed a strong trend toward an increased level of CRP (0.52 vs. 0.34 ng/L,
p = 0.05).
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Table 1. Baseline characteristics.
Variable All Patients Cystatin C< 0.95 mg/mL
Cystatin C
≥ 0.95 mg/mL P Value
No. of Patients n = 31 n = 14 n = 17
Age, years, median (25th–75th) 65 (55–72) 66 (56–72) 65 (51–72) 0.84
Male gender-no. (%) 26 (84) 11 (79) 15 (88) 0.63
Risk Factors
Hypercholesterolemia-no. (%) 19 (61) 8 (57) 11 (64) 0.72
Hypertension-no. (%) 19 (61) 9 (64) 10 (59) 1.00
Smokers-no. (%) 26 (81) 12 (86) 13 (76) 0.66
Family-history of CAD-no. (%) 7 (23) 2 (14) 5 (29) 0.41
Presenting Characteristics
Systolic BP, mmHg, median
(25th–75th) 155 (140–170) 152 (140–170) 160 (150–160) 0.89
Heart rate, pulse/min, mean ± SD 75 (64–88) 84 (75–90) 73 (64–83) 0.06
ECG changes-no. (%) 21 (68) 10 (71) 11 (65) 1.00
Hb, g/dL, median (25th–75th) 14.8 (13.9–15.6) 14.5 (13.9–15.6) 14.9 (14.3–15.6) 0.56
WBC, *103/mm3 median (25th–75th) 8.42 (6.53–12.13) 9.54 (7.57–12.13) 7.62 (6.28–11:03) 0.17
Platelet count, *103/mm3 median
(25th–75th)
254 (209–291) 273 (244–287) 226 (192–291) 0.17
Mean platelet volume, fl median
(25th–75th) 7.4 (7.2–8.3) 7.5 (7.2–10.7) 7.4 (7.2–8.0) 0.35
Creatinine, mg/dL, median
(25th–75th) 0.94 (0.77–1.02) 0.9 (0.76–0.96) 0.94 (0.83–1.02) 0.26
MDRD eGRF, mL/min/1.73, median
(25th–75th) 87 (81–98) 87 (81–100) 97(76–96) 0.49
Cystatin C, mg/dL median
(25th–75th) 0.95 (0.88–1.08) 0.88 (0.79–0.90) 1.04 (0.98–1.22) <0.001
Low density liprotein, mg/dL median
(25th–75th) 136 (106–160) 148 (127–155) 132 (102–161) 0.52
High density liprotein, mg/dL
median (25th–75th) 37 (33–46) 37 (35–39) 38 (33–47) 0.72
CRP, ng/L median (25th–75th) 0.40 (0.24–0.67) 0.52 (0.29–0.95) 0.34 (0.23–0.47) 0.05
LVEF, % median (25th–75th) 57 (50–61) 59 (48–65) 57 (61–60) 0.82
Procedure
Multivessel disease-no. (%) 14 (45) 7 (50) 7 (41) 0.73
Multivessel treatment 12 (38) 7 (50) 5 (29) 0.28
DES-no. (%) 29 (94) 14 (100) 15 (88) 0.48
BP = blood pressure; CAD = coronary artery disease; CRP = c-reactive protein; DES = drug eluting stent; LVEF = left
ventricle ejection fraction, MDRD eGRF = modified diet in renal disease estimated-glomerular filtration rate, WBC =
white blood cell.
Table 2 shows that there were no differences in terms of OCT-assessed features of coronary plaque
vulnerability between the two study groups. Overall, patients with low levels of cystatin C were more
likely to have a higher FDG uptake in the aortic wall and CAC score. When modelled as continuous
variable, cystatin C levels showed a strong trend towards an inverse relationship with the number
of active slices in DA (rho = −0.35, p = 0.06). Yet, after multivariable analysis, levels of cystatin C
were independently associated with FGD uptake in DA as measured by either averaged max TBR
or number of active slices (Table 3). Figure 2A depicts a 18F-FDG-PET/CT scan from a patient in the
high cystatin group showing no significant FDG uptake in the DA (max TBR = 1.3), whilst a further
18F-FDG-PET/CT scan from a patient in the low cystatin C group shows an active (max TBR = 2.0)
focus of FDG uptake in the DA wall (Figure 2B). There were no active slices in the AA, in both cases.
Finally, no trend was found for the association of cystatin C and CAC score. Figure 3 shows that areas
of FDG uptake in the aortic wall are not related to the presence of calcification.
Appl. Sci. 2019, 9, 657 5 of 12
Appl. Sci. 2018, 8, x FOR PEER REVIEW  5 of 13 
 
Figure 1. Study flow chart. Abbreviations: LVEF = left ventricle ejection fraction, MDRD eGRF = 
Modified Diet in Renal Disease estimated Glomerular Filtration Rate, 18F-FDG-PET/CT = 
18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography, FD-OCT = 
Frequency Domain-Optical Coherence Tomography, NSTE-ACS = Non-ST-segment Elevation-Acute 
Coronary Syndrome. 
Table 2 shows that there were no differences in terms of OCT-assessed features of coronary 
plaque vulnerability between the two study groups. Overall, patients with low levels of cystatin C 
were more likely to have a higher FDG uptake in the aortic wall and CAC score. When modelled as 
continuous variable, cystatin C levels showed a strong trend towards an inverse relationship with 
the number of active slices in DA (rho = −0.35, p = 0.06). Yet, after multivariable analysis, levels of 
cystatin C were independently associated with FGD uptake in DA as measured by either averaged 
max TBR or number of active slices (Table 3). Figure 2A depicts a 18F-FDG-PET/CT scan from a 
patient in the high cystatin group showing no significant FDG uptake in the DA (max TBR = 1.3), 
whilst a further 18F-FDG-PET/CT scan from a patient in the low cystatin C group shows an active 
(max TBR = 2.0) focus of FDG uptake in the DA wall (Figure 2B). There were no active slices in the 
AA, in both cases. Finally, no trend was found for the association of cystatin C and CAC score. 
Figure 3 shows that areas of FDG uptake in the aortic wall are not related to the presence of 
calcification. 
Figure 1. Study flow chart. Abbreviations: LVEF = left ventricle ejection fraction, MDRD
eGRF = Modified Diet in Renal Disease estimated Glomerular Filtration Rate, 18F-FDG-PET/CT
= 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography, FD-OCT =
Frequency Domain-Optical Coherence Tomography, NSTE-ACS = Non-ST-segment Elevation-Acute
Coronary Syndrome.
Table 2. Atherosclerotic features as assessed using a multimodality imaging approach according to
cystatin C values.
Variable All Patients Cystatin C<0.95 mg/mL
Cystatin C
≥0.95 mg/mL P Value
No. of Patients n = 31 n = 14 * n = 17
Optical coherenc tomography
Lipid rich plaques, n median (25th–75th) 6 (4–8) 6.5 (5–8) 6 (4–7) 0.55
Lipid rich plaques with macrophages, n
median (25th–75th) 2 (4–5) 4 (3–5) 4 (2–5) 0.78
TCFA, n median (25th–75th) 1 (1–2) 1 (0–3) 1 (1–3) 0.32
18FDG-PET/CT
Averaged mean TBR in AA, median
(25th–75th) 1.23 (1.12–1.30) 1.24 (1.15–1.38) 1.22 (1.09–1.24) 0 23
Averaged max TBR in AA, median (25th–75th) 1.84 (1.71–2.04) 1.95 (1.80–2.21) 1.79 (1.61–1.93) 0.05
Averaged mean TBR in DA, median
(25th–75th) 1.21 (1.02–1.33) 1.29 (1.11–1.41) 1.15 (0.99–1.29) 0.07
Averaged max TBR in DA, median (25th–75th) 1.74 (1.54–1.92) 1.82 (1.62–2.11) 1.61 (1.50–1.84) 0.06
Number of active slices in AA, median (25th
–75th) 11.5 (9–13) 13 (11–14) 11 (9–12) 0.08
Number of active slices in DA, median
(25th–75th) 22.5 (6.5–29) 25 (12–37) 18 (1–24) 0.03
CT scan
Coronary calcium score, median (25th–75th) 955 (224–1300) 1298 (547–1339) 466 (57–1183) 0.07
AA = ascending aorta, DA = descending aorta, TBR = target to background ratio, TCFA = thin cap fibroatheroma.
* 3 patients did not undergo an 18F-FDG-PET/CT scan.
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Table 3. Relation between atherosclerotic features and cystatin C values. Univariable and adjusted
odds ratio * for the highest cystatin C group.
Variable OddsRatio 95% CI P Value
Adjusted
Odds Ratio * 95% CI P Value
Optical coherence tomography
Lipid rich plaques, n 0.87 0.63–1.20 0.40 0.85 0.58–1.24 0.41
Lipid rich plaques with
macrophages, n 1.00 0.69–1.47 0.98 0.82 0.64–1.42 0.81
TCFA, n 1.07 0.65–1.77 0.77 0.98 0.58–1.64 0.94
18FDG-PET/CT
Averaged mean TBR in A, 0.31 0.03–0.62 0.35 0.07 0.0003–14.8 0.33
Averaged max TBR in AA, 0.19 0.002–13.7 0.45 0.19 0.01–3.4 0.26
Averaged mean TBR in DA, 0.017 0.0002–1.49 0.07 0.02 0.00002–1.06 0.053
Averaged max TBR in DA, 0.07 0.004–1.50 0.09 0.02 0.0004–0.89 0.044
Number of active slices in AA, 0.77 0.57–1.06 0.11 0.69 0.47–1.02 0.069
Number of active slices in DA, 0.93 0.87–1.002 0.060 0.89 0.82–0.98 0.025
CT scan
Coronary calcium score, 0.99 0.99–1.00 0.50 0.99 0.99–1.00 0.39
AA = ascending aorta, DA = descending aorta, TBR = target to background ratio, TCFA = thin cap fibroatheroma.
* Adjusted for the C reactive protein and the Modified Diet in Renal Disease estimated Glomerular Filtration Rate.
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Figure 2. Representative 18F-FDG-PET/CT image of thoracic aorta. (A) 18F-FDG-PET/CT image from
a patient in the high cystatin C group (cystatin C = 1.38 mg/mL) showing a non-significant focus
(arrow) of 18F-FDG uptake in the descending aortic wall with a TBRmax of 1.3 (18F-FDG-PET slices are
defined as active if TBRmax is ≥1.6) (B) 18F-FDG-PET/CT image from a patient in the low cystatin
C group (cystatin C = 0.84 mg/mL) showing an active focus of 18F-FDG uptake in the descending
aorta with a TBRmax of 2.0 (arrow) and a non-active focal 18F-FDG uptake (arrowhead; TBRmax = 1.5) in
the ascending aorta. Abbreviations: 18F-FDG-PET/CT = 18F-fluorodeoxyglucose-positron emission
tomography/computed tomography; LV = left ventricle; TBR = target to background ratio.
Appl. Sci. 2019, 9, 657 7 of 12
Appl. Sci. 2018, 8, x FOR PEER REVIEW  7 of 13 
Figure 2. Representative 18F-FDG-PET/CT image of thoracic aorta. A) 18F-FDG-PET/CT image from a 
patient in the high cystatin C group (cystatin C = 1.38 mg/ml) showing a non-significant focus 
(arrow) of 18F-FDG uptake in the descending aortic wall with a TBRmax of 1.3 (18F-FDG-PET slices are 
defined as active if TBRmax is ≥1.6) B) 18F-FDG-PET/CT image from a patient in the low cystatin C 
group (cystatin C = 0.84 mg/ml) showing an active focus of 18F-FDG uptake in the descending aorta 
with a TBRmax of 2.0 (arrow) and a non-active focal 18F-FDG uptake (arrowhead; TBRmax = 1.5) in the 
ascending aorta. Abbreviations: 18F-FDG-PET/CT = 18F-fluorodeoxyglucose-positron emission 
tomography/computed tomography; LV = left ventricle; TBR = target to background ratio. 
 
Figure 3. Representative 18F-FDG-PET/CT image of thoracic aorta showing a big focal calcification 
(arrowhead) not related to significant 18F-FDG uptake (TBRmax = 1.3). In the descending aorta, an 
active focal 18F-FDG uptake (arrow) is also shown (TBRmax = 1.8). Abbreviations: 18F-FDG-PET/CT = 
18F-fluorodeoxyglucose-positron emission tomography/computed tomography; TBR = target to 
background ratio. 
Table 3. Relation between atherosclerotic features and cystatin C values. Univariable and adjusted 
odds ratio* for the highest cystatin C group. 
Variable 
Odds 
Ratio 
95% CI P Value 
Adjusted 
Odds 
Ratio* 
95% CI P Value 
Optical coherence 
tomography 
      
Lipid rich plaques, n  0.87 0.63–1.20 0.40 0.85 0.58–1.24 0.41 
Lipid rich plaques with 
macrophages, n  
1.00 0.69–1.47 0.98 0.82 0.64–1.42 0.81 
TCFA, n  1.07 0.65–1.77 0.77 0.98 0.58–1.64 0.94 
18FDG-PET/CT       
Averaged mean TBR in 
A, 
0.31 0.03–0.62 0.35 0.07 0.0003–14.8 0.33 
Averaged max TBR in 0.19 0.002–13.7 0.45 0.19 0.01–3.4 0.26 
Figure 3. Representative 18F-FDG-PET/CT i age of thoracic aorta showing a big focal calcification
(arrowhead) not related to significant 18F-FDG uptake (TBRmax = 1.3). In the descending aorta, an active
focal 18F-FDG uptake (arrow) is also shown (TBRmax = 1.8). Abbreviations: 18F-FDG-PET/CT =
18F-fluorodeoxyglucose-positron emission tomography/computed tomography; TBR = target to
background ratio.
4. Discussion
The main findings of the prese t study enrolling 31 patients with first NSTE-ACS undergoing
PCI are as follows: 1) thoracic DA inflammation as assessed using 18F-FDG-PET/CT and expressed
in terms of TBR was independently associated with low levels of serum cystatin C; 2) there was no
relationship between cystatin C levels and either features of coronary plaque vulnerability as assessed
using OCT or CAC score as assessed using a CT scan.
During the past decade, cystatin C, a 13-kDa protein and member of a family of competitive
inhibitors of lysosomal cysteine proteases, has gained great popularity because it has been consistently
shown to be a more reliable marker of renal function than creatinine [2,3]. Yet, high levels of
cystatin C have been associated with an adverse cardiovascular outcome in several observational
studies involving patients with a broad spectrum of clinical conditions [4,5]. These findings, along
with the observation that elastolytic cysteine proteases and their inhibitors, in particular cystatin C,
are involved in the pathogenesis of atherosclerosis [8,9], have led many researchers to thoroughly
investigate the link between high levels of cystatin C and impaired cardiovascular outcome. At least
partially, some studies have recently shed light on this topic. First, based on the fact that several
single nucleotide polymorphisms are associated with circulating cystatin C level [22,23], prospective
observational studies [24,25] and mendelian randomization studies [10,11] have shown that high levels
of cystatin C are not causally related to the incidence of coronary artery disease, ischemic stroke,
and heart failure. In particular, mendelian randomization studies rely on a very large sample size
and on the fact that genetic information, randomly distributed from parents to offspring, are not
influenced by either disease status (reverse causality) or potential confounders. Secondly, it has
been demonstrated that cystatin C is a more reliable marker of renal function than creatinine. It is
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able to detect a small reduction in renal function that may promote atherosclerosis and an adverse
outcome [7]. However, whether high levels of cystatin C are independently related to the burden of
atherosclerosis (reverse causality) is, on the contrary, still controversial, with some clinical studies
using angiography showing a direct [26] relationship with the extent of coronary disease and others
an inverse relationship [27]. In the present study, we used a multi-imaging approach to test in vivo the
relationship between serum levels of cystatin C and different features of atherosclerosis in patients
with NSTE-ACS and nearly normal renal function. First, FD-OCT is a recently developed optical
imaging invasive technique that provides high-resolution and cross-sectional images of coronary tissue
in situ [28]. The resolution of FD-OCT (about 10 µm) is appropriate for measuring cap thickness
and even plaque macrophage density. We showed that serum levels of cystatin C are not related
to features of coronary plaque vulnerability, namely the number of lipid-rich plaques, lipid-rich
plaques with macrophages, and TCFAs. Secondly, micro- and macro-calcification are a cardinal
characteristic of atherosclerotic plaques and a hallmark of the inflammatory process [29]. CAC scoring
by Agatston et al. [20] is associated with the extent of coronary plaque burden [30] and in clinical
practice is considered a reliable marker of cardiovascular risk [31]. In the present study, although
patients with low levels of cystatin C showed a lower median value of CAC score, we did not find
any statistically significant association after univariable and multivariable analysis. These findings
contrast with those observed by Imai et al. [32] who found a positive correlation between Agatston
score and cystatin C levels in 410 stable patients. These discrepancies may be related to both different
clinical setting and different sample size. Thirdly, unlike the previous imagine techniques that provide
just morphological information, 18F-FDG-PET is a molecular noninvasive imaging technique that
reports on the metabolic activity of atherosclerosis since glucose is the major substrate for macrophages
resident in plaque [33]. 18F-FDG uptake in macrophages is positively correlated with the level of
pro-inflammatory activation [34]. Accordingly, the relationship between arterial 18F-FDG signal and
plaque macrophage infiltration has been reported both in animal models [35] and humans, especially
at the level of carotid plaques, aorta, and iliac-femoral arteries [36–38]. In the present study, we found
that 18F-FDG uptake in the thoracic DA was associated with low levels of serum cystatin C after
adjustment for CRP and eGRF. This association was not observed for the 18F-FDG uptake in the AA
wall suggesting that the presence of atherosclerotic plaques increases substantially from the ascending
aorta to the descending aorta [39]. Therefore, findings of the present study support in vivo data
obtained from experimental studies showing that macrophage activation in atherosclerotic lesions
is associated with an increased level of elastolytic cathepsins and decreased level of their inhibitors,
such as cystatin C [40,41]. Notably, our study had several exclusion criteria aimed at excluding cardiac
and non-cardiac conditions that may be associated with either secondary forms of acute coronary
syndrome or release of pro-inflammatory mediators. In particular, patients with heart failure [42],
corticoid treatment [43], and thyroid dysfunction [44] that may have influenced circulating cystatin C
levels were excluded. Taken together, the findings of our study do not support the theory that high
levels of cystatin C are independently associated with the extent of coronary disease. On the contrary,
we showed that metabolic plaque activity in the DA wall was associated with low levels of serum
cystatin C. Given these observations and the available literature, we suggest that high levels of cystatin
C represent mainly a marker of renal function abnormalities that promote impaired outcome, rather
than a marker of atherosclerosis.
The results of the present study should be interpreted with caution in light of some limitations.
Since no data were available regarding the relationship between FDG uptake in the aortic wall and
serum cystatin C levels we were prevented from calculating the sample size a priori. Nonetheless,
we found a statistically significant association between FDG uptake in the DA and cystatin C levels.
However, this finding showed a certain degree of imprecision with wide confidence intervals.
As mentioned above, owing to our small sample size we could have missed some significant
relationship as well.
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Although the 2 study groups were well balanced in terms of baseline characteristics, the effect of
unknown confounders on cystatin C values cannot be ruled out. In particular, we do not know the
distribution of genetic polymorphisms in the study population.
Because of several technical issues such as 18F-FDG -PET low spatial resolution, small size
of coronary plaques, cardiac motion, and myocardium avidity for glucose as energetic substrate,
using 18F-FDG-PET to measure inflammation in coronary artery plaques is suboptimal [45]. Conversely,
18F-sodium fluoride [45] has been shown to better identify coronary plaques with high-risk features,
but this was beyond the scope of our study. However, it has been extensively demonstrated
that 18F-FDG activity in the great artery wall such as the aorta or the carotid arteries correlates
with macrophage infiltration along with other features of plaque vulnerability [38,46,47], is highly
reproducible [48], and predicts outcome [49]. These characteristics have led to an increasing
use of 18F-FDG-PET as surrogate endpoint in trials of novel therapies endpoint [50] and makes
this tool particularly suitable for studies like ours aimed at exploring the association between an
imputed biomarker of atherosclerosis and the metabolic activity within the atheroma. Nonetheless,
the utilization of other PET tracer such as 18F-sodium fluoride would allow the evaluation of
the association between biomarkers and intimal micro-calcification that have also been associated
with plaque vulnerability and progression [51]. Yet, dual-tracer 18F-FDG-18F-sodium fluoride
PET/Magnetic Resonance [52] or CT [53] have been suggested for in vivo simultaneous clinical
evaluation of both inflammation and micro-calcification that might increase understanding of
mechanisms of atherosclerosis.
5. Conclusions
In patients with first NSTEACS, 18F-FDG uptake in the DA was independently associated with
a low level of serum cystatin C. There was no relationship between cystatin C levels and features
of coronary plaque vulnerability as assessed using OCT or CAC score as assessed using CT scan.
These findings suggest that high levels of CysC may not be considered as independent markers
of atherosclerosis.
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